BeautyHealth Q2 net sales $117.5M (+13% YoY); net income $3.4M; reaffirms FY guidance

SkinHealth Systems Inc.

2023-Q2 EPS reported -$0.13 revenue$203,757,000

Net sales $117.5M (+13% YoY); net income $3.4M; adjusted EBITDA margin 15.1%.
Reaffirms 2023 net sales and 2025 guidance; refines 2023 adj. EBITDA margin to 18%-19%.
Consumables net sales +34% YoY; delivery systems +1% (or +30% ex trade-ups).
APAC net sales +143% YoY (China +265%); partner LaserAway for Syndeo at 125+ locations.
FDA clearance for SkinStylus for facial acne scarring; AWS collaboration for generative AI.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SkinHealth Systems Inc. reported the second quarter ended June 30, 2023 results: revenue $117.5 million, net income $3.4 million. Guidance reaffirmed.

Period: the second quarter ended June 30, 2023
Revenue: $117.5 million
Net income: $3.4 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

For the quarter, net sales of $117.5 million increased +13% year-over-year, or +32% excluding trade-ups, continuing a trend of double-digit quarterly growth. Net income was $3.4 million, and adjusted EBITDA margin was 15.1% for the quarter. On the momentum, the Company re-affirms its 2023 net sales and long-term 2025 financial guidance, and refines its 2023 adjusted EBITDA margin to a more precise 18%-19% range.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

SkinHealth Systems Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-028406

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.